MiMedx off lows, still down 33% after FDA posts letter


Shares of biomaterial products maker MiMedx are off their lows, but remain down 35% to $3.95 after the FDA posted on its website a letter to the company dated August 28. The letter stated MiMedx's Surgical Biologics unit violated the Public Health Service Act after on its units market unapproved biologics products.

View Comments (0)